The lowest and highest of the models that produced a value. This is the spread of the methods, not a price target.
Price target range & 52-week position
Bear¥2,318.12Fair value¥4,591.02Bull¥7,015.24
FairClose
52-week traded range
52W low ¥3,175.0052W high ¥5,400.00
The 52-week range is measured from the stored price history, not estimated.
Valuation summary
Trading below the consensus fair value
Genky DrugStores Co.,Ltd. closed at ¥3,445.00, 25.0% below the consensus fair value of ¥4,591.02 drawn from 8 valuation models.
Financial DNA score 40/100 — Average. P/E of 13.3x against the 20x sector multiple the P/E model uses.
Quantitative summary only — not investment advice.
All valuation models
DCF Valuation
¥4,615.10
+34.0%
Σ[CF×(1+g)^n/(1.10)^n] + TV/(1.10)^10
g=9%, r=10%, tg=3%, n=10yr
Graham Number
¥3,024.64
-12.2%
√(22.5 × EPS × BVPS)
EPS=232.51, BVPS=1748.73 · outside Graham range (P/E 14.8, P/B 2) — asset-light, treat as a rough floor
P/E Fair Value
¥4,650.20
+35.0%
EPS × 20x (sector P/E)
EPS=232.51, Sector P/E=20x
Peter Lynch (PEG)
¥2,318.12
-32.7%
EPS × Growth% (PEG = 1 is fair)
EPS=232.51, g=10%
EV/EBITDA
¥7,015.24
+103.6%
(EBITDA × 15x − Net Debt) ÷ Shares
EBITDA=15.95B
Book Value (P/B)
¥3,584.90
+4.1%
BVPS × (ROE−g)÷(r−g) [Justified P/B — RIM-based]
BVPS=1748.73, ROE=14.2%, g=6%, r=10%
Reverse DCF
¥3,445.00
+0.0%
Solve for g: Price = Σ[EPS×(1+g)^n/(1.10)^n] + TV
Implied: 3.1% | Historical: 10%
Margin of Safety
¥3,072.48
-10.8%
Avg(DCF, Graham, P/E) × 75% (25% safety buffer)
Avg fair value=4096.65, MoS=25%
Computed on September 12, 2026 from the most recent annual report on file and that day's closing price. Where a company has seen its earnings move sharply since its last annual report, this figure will lag the market.
Educational data only. Not a recommendation to buy, sell or hold any security.